DeepMed Research

PIERRE FABRE MEDICAMENT

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

Phase 3

Completed

Conditions: Recurrent Upper-Respiratory Tract Infections

Interventions: Drug: J022X ST
Drug: Placebo

First Posted Date: 2013-09-24

Last Posted Date: 2017-02-03

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 1003

Registration Number: NCT01948856

Evaluation and Comparison of Systemic Exposure to Ibuprofen After Single Oromucosal Versus Oral Administrations

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: V0498 - A mg
Drug: Ibuprofen

First Posted Date: 2013-05-21

Last Posted Date: 2013-06-24

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 26

Registration Number: NCT01859377

Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Vinorelbine cisplatin radiotherapy

First Posted Date: 2013-04-24

Last Posted Date: 2013-04-24

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 70

Registration Number: NCT01839032

Locations: 🇫🇷
CHU CAEN, Caen, France

Efficacy and Safety Study of F373280

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: 1g of F373280
Drug: Placebo

First Posted Date: 2013-04-15

Last Posted Date: 2019-07-02

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 135

Registration Number: NCT01831856

Ibuprofen Lozenge in Acute Sore Throat Pain

Phase 3

Completed

Conditions: Acute Sore Throat Pain

Interventions: Drug: Ibuprofen 25 mg
Drug: Placebo

First Posted Date: 2013-02-07

Last Posted Date: 2013-06-27

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 427

Registration Number: NCT01785862

Emollients in the Management of Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: glycerol, paraffin (liquid and white soft)
Device: Atopiclair®
Drug: Locatop@
Drug: Locapred@

First Posted Date: 2013-01-30

Last Posted Date: 2014-02-19

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 347

Registration Number: NCT01779258

Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia

Phase 1

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Tardyferon 80 mg

First Posted Date: 2012-12-28

Last Posted Date: 2014-04-15

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 55

Registration Number: NCT01757119

Brain Imaging Study of F17464

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: F17464

First Posted Date: 2012-09-20

Last Posted Date: 2013-02-15

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 8

Registration Number: NCT01689038

Nicotine Patch Bioequivalence Study

Phase 1

Completed

Conditions: Healthy Smokers

Interventions: Drug: V0116 transdermal patch (Test treatment )
Drug: Nicotine transdermal patch (Reference Treatment )

First Posted Date: 2012-08-06

Last Posted Date: 2012-12-11

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 28

Registration Number: NCT01658202

Nicotine Patch - Multidose Bioequivalence Study

Phase 1

Completed

Conditions: Healthy Smokers

Interventions: Drug: V0116 transdermal patch (Test treatment )
Drug: Nicotine transdermal patch (Reference treatment )

First Posted Date: 2012-08-06

Last Posted Date: 2012-12-11

Lead Sponsor: Pierre Fabre Medicament

Target Recruit Count: 43

Registration Number: NCT01658215

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy